Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 14 · newest first

  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine · 2016
  2. Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)Leukemia · 2016
  3. Vosaroxin: innovative anticancer quinolone for the treatment of acute myelogenous leukemiaExpert Opinion on Orphan Drugs · 2016
  4. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaBlood · 2016
  5. Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesCancer · 2016
  6. Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood · 2016
  7. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJournal of Clinical Oncology · 2016
  8. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibitionSHILAP Revista de lepidopterología · 2016
  9. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.Journal of Clinical Oncology · 2016
  10. Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034American Journal of Hematology · 2016
  11. Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimenAmerican Journal of Hematology · 2016
  12. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysisHaematologica · 2016
  13. Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemiaAmerican Journal of Hematology · 2016
  14. Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyBlood Cancer Journal · 2016
  15. Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesCancer · 2016
  16. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemiaLeukemia · 2016
  17. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD–Positive Acute Myelogenous LeukemiaBiology of Blood and Marrow Transplantation · 2016
  18. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyBlood · 2016
  19. Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignanciesCancer · 2016
  20. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureHaematologica · 2016
  21. Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinibAmerican Journal of Hematology · 2016
  22. Acute myeloid leukemia: advancing clinical trials and promising therapeuticsExpert Review of Hematology · 2016
  23. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesScience Signaling · 2016
  24. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsOncotarget · 2016
  25. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomesBritish Journal of Haematology · 2016
  26. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia · 2016
  27. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2016
  28. Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid LeukemiaFuture Oncology · 2016
  29. Role of Inotuzumab Ozogamicin in the Treatment of Relapsed/Refractory Acute Lymphoblastic LeukemiaImmunotherapy · 2016
  30. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeBlood · 2016
  31. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Clinical Lymphoma Myeloma & Leukemia · 2016
  32. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsBlood · 2016
  33. CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast countLeukemia & lymphoma/Leukemia and lymphoma · 2016
  34. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapyCancer · 2015
  35. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analysesBlood Cancer Journal · 2015
  36. Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer CenterBritish Journal of Haematology · 2015
  37. Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with BlinatumomabBlood · 2015
  38. The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort StudiesBlood · 2015
  39. Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaBlood · 2015
  40. Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)Blood · 2015
  41. Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 TrialBlood · 2015
  42. Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Blood · 2015
  43. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ MalignanciesBlood · 2015
  44. Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic LeukemiaBlood · 2015
  45. Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE TrialBlood · 2015
  46. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Cell Reports · 2015
  47. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsBlood · 2015
  48. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)American Journal of Hematology · 2015
  49. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid LeukemiaJNCI Journal of the National Cancer Institute · 2015
  50. Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinibBritish Journal of Haematology · 2015